Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel

PURPOSE: For patients with metastatic castration-resistant prostatic cancer (mCRPC), docetaxel plus prednisone leads to superior survival and a higher response rate compared with mitoxantrone plus prednisone. We analyzed the efficacy of long-term treatment with ≥10 cycles of docetaxel, and validated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Miyoshi, Yasuhide, Sekiguchi, Zenkichi, Sano, Futoshi, Hayashi, Narihiko, Teranishi, Jun-ichi, Misaki, Hiroshi, Noguchi, Kazumi, Kubota, Yoshinobu, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484044/
https://www.ncbi.nlm.nih.gov/pubmed/23118948
http://dx.doi.org/10.1371/journal.pone.0048186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484044/
https://www.ncbi.nlm.nih.gov/pubmed/23118948
http://dx.doi.org/10.1371/journal.pone.0048186

Ejemplares similares